Arrowhead Pharmaceuticals (ARWR) Stock Forecast, Price Target & Predictions
ARWR Stock Forecast
Arrowhead Pharmaceuticals stock forecast is as follows: an average price target of $45.38 (represents a 144.37% upside from ARWR’s last price of $18.57) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
ARWR Price Target
The average price target for Arrowhead Pharmaceuticals (ARWR) is $45.38 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $75.00 to $27.00. This represents a potential 144.37% upside from ARWR's last price of $18.57.
ARWR Analyst Ratings
According to 10 Wall Street analysts, Arrowhead Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ARWR stock is 0 'Strong Buy' (0.00%), 7 'Buy' (70.00%), 3 'Hold' (30.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Arrowhead Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 03, 2024 | David Lebowitz | Citigroup | $27.00 | $22.91 | 17.85% | 45.40% |
| Jul 05, 2024 | Patrick Trucchio | H.C. Wainwright | $60.00 | $25.57 | 134.65% | 223.10% |
| Jun 05, 2024 | Andrea Tan | Goldman Sachs | $31.00 | $25.29 | 22.58% | 66.94% |
| May 30, 2024 | Luca Issi | RBC Capital | $50.00 | $22.87 | 118.63% | 169.25% |
| Feb 07, 2023 | - | RBC Capital | $77.00 | $32.94 | 133.76% | 314.65% |
| Feb 07, 2023 | - | Piper Sandler | $52.00 | $33.51 | 55.18% | 180.02% |
| Dec 06, 2022 | - | H.C. Wainwright | $90.00 | $31.52 | 185.53% | 384.65% |
| Nov 29, 2022 | - | Jefferies | $75.00 | $29.99 | 150.08% | 303.88% |
| Nov 29, 2022 | - | Morgan Stanley | $37.00 | $28.00 | 32.14% | 99.25% |
| Nov 29, 2022 | - | Leerink Partners | $31.00 | $28.00 | 10.71% | 66.94% |
The latest Arrowhead Pharmaceuticals stock forecast, released on Sep 03, 2024 by David Lebowitz from Citigroup, set a price target of $27.00, which represents a 17.85% increase from the stock price at the time of the forecast ($22.91), and a 45.40% increase from ARWR last price ($18.57).
Arrowhead Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 4 |
| Avg Price Target | - | $27.00 | $42.00 |
| Last Closing Price | $18.57 | $18.57 | $18.57 |
| Upside/Downside | -100.00% | 45.40% | 126.17% |
In the current month, the average price target of Arrowhead Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Arrowhead Pharmaceuticals's last price of $18.57. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 03, 2024 | Citigroup | Neutral | Neutral | Hold |
| Aug 21, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 15, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 05, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 05, 2024 | Goldman Sachs | - | Neutral | Initialise |
| May 30, 2024 | RBC Capital | Outperform | Outperform | Hold |
| May 24, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 20, 2024 | Citigroup | Neutral | Neutral | Hold |
Arrowhead Pharmaceuticals's last stock rating was published by H.C. Wainwright on Oct 14, 2024. The company gave ARWR a "Buy" rating, the same as its previous rate.
Arrowhead Pharmaceuticals Financial Forecast
Arrowhead Pharmaceuticals Revenue Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $3.55M | $16.10M | $15.82M | $146.27M | $62.55M | $31.57M | $32.41M | $151.81M | $27.44M | $38.28M | $45.89M | $32.81M | $21.30M | $7.63M | $27.38M | $23.53M | $29.45M | $43.29M | $42.70M | $48.15M | $650.13K | $8.99M | $43.75K |
| Avg Forecast | $29.99M | $24.51M | $18.74M | $15.49M | $55.07M | $52.87M | $41.97M | $33.87M | $44.63M | $45.42M | $45.48M | $162.52M | $50.30M | $45.75M | $122.15M | $47.81M | $42.19M | $43.47M | $39.42M | $106.12M | $57.76M | $30.42M | $22.16M | $31.08M | $40.98M | $54.37M | $42.92M | $650.00K | $13.48M | $42.28K |
| High Forecast | $29.99M | $24.51M | $18.74M | $15.49M | $119.19M | $52.87M | $41.97M | $68.58M | $179.39M | $45.42M | $45.48M | $162.52M | $50.30M | $45.75M | $122.15M | $47.81M | $42.19M | $43.47M | $39.42M | $106.12M | $57.76M | $30.42M | $22.16M | $31.08M | $40.98M | $54.37M | $42.92M | $780.00K | $16.18M | $50.74K |
| Low Forecast | $29.99M | $24.51M | $18.74M | $15.49M | $9.15M | $52.87M | $41.97M | $838.37K | $3.52M | $45.42M | $45.48M | $162.52M | $50.30M | $45.75M | $122.15M | $47.81M | $42.19M | $43.47M | $39.42M | $106.12M | $57.76M | $30.42M | $22.16M | $31.08M | $40.98M | $54.37M | $42.92M | $520.00K | $10.79M | $33.83K |
| # Analysts | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 | 10 | 16 |
| Surprise % | - | - | - | - | - | - | - | 0.10% | 0.36% | 0.35% | 3.22% | 0.38% | 0.63% | 0.71% | 1.24% | 0.57% | 0.91% | 1.06% | 0.83% | 0.20% | 0.13% | 0.90% | 1.06% | 0.95% | 1.06% | 0.79% | 1.12% | 1.00% | 0.67% | 1.03% |
Arrowhead Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 4 analysts is $41.97M, with a low forecast of $41.97M, and a high forecast of $41.97M. ARWR's average Quarter revenue forecast represents a 1081.94% increase compared to the company's last Quarter revenue of $3.55M (Dec 23).
Arrowhead Pharmaceuticals EBITDA Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 | 10 | 16 |
| EBITDA | - | - | - | - | - | - | - | $-129.06M | $-99.87M | $-94.95M | $55.40M | $-42.13M | $-83.83M | $-70.31M | $44.15M | $-60.30M | $-60.87M | $-27.93M | $-24.90M | $-18.88M | $-46.66M | $-12.07M | $-18.46M | $-1.41M | $12.96M | $21.34M | $25.07M | $-13.73M | $-4.85M | $-20.01M |
| Avg Forecast | $-17.74M | $-14.50M | $-11.09M | $-9.17M | $-32.58M | $-31.28M | $-24.83M | $-20.04M | $-26.41M | $-26.87M | $-26.91M | $-37.59M | $-31.36M | $-28.53M | $-76.17M | $-29.82M | $-26.31M | $-27.11M | $-27.39M | $-66.17M | $-36.02M | $-18.97M | $-9.57M | $-19.38M | $-25.55M | $-33.90M | $18.47M | $-13.73M | $-6.47M | $-21.09M |
| High Forecast | $-17.74M | $-14.50M | $-11.09M | $-9.17M | $-5.42M | $-31.28M | $-24.83M | $-495.99K | $-2.08M | $-26.87M | $-26.91M | $-30.07M | $-31.36M | $-28.53M | $-76.17M | $-29.82M | $-26.31M | $-27.11M | $-21.91M | $-66.17M | $-36.02M | $-18.97M | $-7.66M | $-19.38M | $-25.55M | $-33.90M | $22.17M | $-10.98M | $-5.18M | $-16.87M |
| Low Forecast | $-17.74M | $-14.50M | $-11.09M | $-9.17M | $-70.52M | $-31.28M | $-24.83M | $-40.57M | $-106.13M | $-26.87M | $-26.91M | $-45.10M | $-31.36M | $-28.53M | $-76.17M | $-29.82M | $-26.31M | $-27.11M | $-32.87M | $-66.17M | $-36.02M | $-18.97M | $-11.49M | $-19.38M | $-25.55M | $-33.90M | $14.78M | $-16.48M | $-7.77M | $-25.31M |
| Surprise % | - | - | - | - | - | - | - | 6.44% | 3.78% | 3.53% | -2.06% | 1.12% | 2.67% | 2.46% | -0.58% | 2.02% | 2.31% | 1.03% | 0.91% | 0.29% | 1.30% | 0.64% | 1.93% | 0.07% | -0.51% | -0.63% | 1.36% | 1.00% | 0.75% | 0.95% |
5 analysts predict ARWR's average Quarter EBITDA for Jun 23 to be $-26.87M, with a high of $-26.87M and a low of $-26.87M. This is -148.50% lower than Arrowhead Pharmaceuticals's previous annual EBITDA (Mar 23) of $55.40M.
Arrowhead Pharmaceuticals Net Income Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 | 10 | 16 |
| Net Income | - | - | - | - | - | - | - | $-132.86M | $-109.68M | $-102.95M | $48.67M | $-41.81M | $-85.94M | $-71.18M | $44.37M | $-62.87M | $-63.37M | $-29.92M | $-26.82M | $-20.73M | $-48.43M | $-13.61M | $-19.84M | $-2.67M | $11.70M | $20.34M | $23.90M | $-14.88M | $-6.04M | $-20.82M |
| Avg Forecast | $-141.99M | $-152.46M | $-159.66M | $-158.33M | $-120.53M | $-65.69M | $248.71M | $-99.49M | $-75.59M | $-70.71M | $266.00M | $-39.19M | $-72.53M | $-70.62M | $284.50M | $-55.50M | $5.94M | $-17.11M | $-29.50M | $15.06M | $12.31M | $-14.28M | $-10.29M | $2.66M | $20.40M | $35.27M | $17.61M | $-14.88M | $-8.06M | $-21.94M |
| High Forecast | $-141.99M | $-152.46M | $-159.66M | $-158.33M | $103.31M | $-65.69M | $298.46M | $-36.99M | $94.48M | $-70.71M | $319.21M | $-31.35M | $-72.53M | $-70.62M | $341.40M | $-55.50M | $5.94M | $-17.11M | $-23.60M | $15.06M | $12.31M | $-14.28M | $-8.23M | $2.66M | $20.40M | $35.27M | $21.13M | $-11.91M | $-6.45M | $-17.55M |
| Low Forecast | $-141.99M | $-152.46M | $-159.66M | $-158.33M | $-285.05M | $-65.69M | $198.97M | $-142.85M | $-124.72M | $-70.71M | $212.80M | $-47.03M | $-72.53M | $-70.62M | $227.60M | $-55.50M | $5.94M | $-17.11M | $-35.40M | $15.06M | $12.31M | $-14.28M | $-12.34M | $2.66M | $20.40M | $35.27M | $14.09M | $-17.86M | $-9.67M | $-26.33M |
| Surprise % | - | - | - | - | - | - | - | 1.34% | 1.45% | 1.46% | 0.18% | 1.07% | 1.18% | 1.01% | 0.16% | 1.13% | -10.67% | 1.75% | 0.91% | -1.38% | -3.93% | 0.95% | 1.93% | -1.00% | 0.57% | 0.58% | 1.36% | 1.00% | 0.75% | 0.95% |
Arrowhead Pharmaceuticals's average Quarter net income forecast for Jun 23 is $-70.71M, with a range of $-70.71M to $-70.71M. ARWR's average Quarter net income forecast represents a -245.26% decrease compared to the company's last Quarter net income of $48.67M (Mar 23).
Arrowhead Pharmaceuticals SG&A Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 | 10 | 16 |
| SG&A | - | - | - | - | - | - | - | $23.19M | $24.17M | $23.37M | $22.82M | $20.98M | $33.24M | $32.74M | $33.86M | $24.59M | $38.29M | $17.86M | $16.19M | $8.65M | $14.27M | $10.75M | $16.33M | $10.79M | $10.27M | $4.81M | $5.33M | $3.68M | $6.95M | $10.48M |
| Avg Forecast | $13.35M | $10.91M | $8.35M | $6.90M | $24.52M | $23.54M | $18.69M | $15.08M | $19.87M | $20.23M | $20.25M | $15.33M | $22.46M | $20.43M | $54.55M | $21.35M | $18.84M | $19.41M | $17.81M | $47.39M | $25.80M | $13.59M | $8.47M | $13.88M | $18.30M | $24.28M | $3.93M | $290.30K | $9.27M | $18.88K |
| High Forecast | $13.35M | $10.91M | $8.35M | $6.90M | $53.07M | $23.54M | $18.69M | $30.54M | $79.88M | $20.23M | $20.25M | $18.39M | $22.46M | $20.43M | $54.55M | $21.35M | $18.84M | $19.41M | $21.37M | $47.39M | $25.80M | $13.59M | $10.16M | $13.88M | $18.30M | $24.28M | $4.72M | $348.36K | $11.12M | $22.66K |
| Low Forecast | $13.35M | $10.91M | $8.35M | $6.90M | $4.08M | $23.54M | $18.69M | $373.30K | $1.57M | $20.23M | $20.25M | $12.26M | $22.46M | $20.43M | $54.55M | $21.35M | $18.84M | $19.41M | $14.25M | $47.39M | $25.80M | $13.59M | $6.77M | $13.88M | $18.30M | $24.28M | $3.14M | $232.24K | $7.41M | $15.11K |
| Surprise % | - | - | - | - | - | - | - | 1.54% | 1.22% | 1.16% | 1.13% | 1.37% | 1.48% | 1.60% | 0.62% | 1.15% | 2.03% | 0.92% | 0.91% | 0.18% | 0.55% | 0.79% | 1.93% | 0.78% | 0.56% | 0.20% | 1.36% | 12.68% | 0.75% | 555.17% |
Arrowhead Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $18.69M, based on 4 Wall Street analysts, with a range of $18.69M to $18.69M. The forecast indicates a -19.42% fall compared to ARWR last annual SG&A of $23.19M (Dec 23).
Arrowhead Pharmaceuticals EPS Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 | 10 | 16 |
| EPS | - | - | - | - | - | - | - | $-1.24 | $-1.03 | $-0.96 | $0.46 | $-0.39 | $-0.81 | $-0.67 | $0.42 | $-0.60 | $-0.61 | $-0.29 | $-0.26 | $-0.20 | $-0.47 | $-0.13 | $-0.20 | $-0.03 | $0.12 | $0.21 | $0.25 | $-0.18 | $-0.08 | $-0.35 |
| Avg Forecast | $-1.14 | $-1.23 | $-1.29 | $-1.27 | $-0.97 | $-0.53 | $-0.47 | $-0.80 | $-0.61 | $-0.57 | $-0.62 | $0.37 | $-0.58 | $-0.57 | $0.14 | $-0.45 | $0.05 | $-0.14 | $0.10 | $0.12 | $0.10 | $-0.12 | $-0.11 | $0.02 | $0.16 | $0.28 | $0.20 | $-0.18 | $-0.16 | $-0.39 |
| High Forecast | $-1.14 | $-1.23 | $-1.29 | $-1.27 | $0.83 | $-0.53 | $-0.47 | $-0.30 | $0.76 | $-0.57 | $-0.62 | $0.37 | $-0.58 | $-0.57 | $0.14 | $-0.45 | $0.05 | $-0.14 | $0.10 | $0.12 | $0.10 | $-0.12 | $-0.11 | $0.02 | $0.16 | $0.28 | $0.20 | $-0.14 | $-0.13 | $-0.31 |
| Low Forecast | $-1.14 | $-1.23 | $-1.29 | $-1.27 | $-2.30 | $-0.53 | $-0.47 | $-1.15 | $-1.00 | $-0.57 | $-0.62 | $0.37 | $-0.58 | $-0.57 | $0.14 | $-0.45 | $0.05 | $-0.14 | $0.10 | $0.12 | $0.10 | $-0.12 | $-0.11 | $0.02 | $0.16 | $0.28 | $0.20 | $-0.22 | $-0.19 | $-0.47 |
| Surprise % | - | - | - | - | - | - | - | 1.55% | 1.69% | 1.69% | -0.74% | -1.05% | 1.39% | 1.18% | 2.90% | 1.34% | -12.68% | 2.11% | -2.52% | -1.65% | -4.75% | 1.13% | 1.85% | -1.40% | 0.73% | 0.74% | 1.26% | 1.00% | 0.50% | 0.90% |
According to 5 Wall Street analysts, Arrowhead Pharmaceuticals's projected average Quarter EPS for Jun 23 is $-0.57, with a low estimate of $-0.57 and a high estimate of $-0.57. This represents a -223.76% decrease compared to ARWR previous annual EPS of $0.46 (Mar 23).
Arrowhead Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CTMX | CytomX Therapeutics | $0.91 | $5.73 | 529.67% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.31 | $38.80 | 191.51% | Buy |
| APLS | Apellis Pharmaceuticals | $26.27 | $74.50 | 183.59% | Buy |
| ARWR | Arrowhead Pharmaceuticals | $18.57 | $45.38 | 144.37% | Buy |
| TERN | Terns Pharmaceuticals | $6.17 | $14.25 | 130.96% | Buy |
| ANNX | Annexon | $6.12 | $14.00 | 128.76% | Buy |
| ASMB | Assembly Biosciences | $16.14 | $35.50 | 119.95% | Buy |
| WVE | Wave Life Sciences | $13.67 | $22.14 | 61.96% | Buy |
| BMRN | BioMarin Pharmaceutical | $63.42 | $101.70 | 60.36% | Buy |
| IONS | Ionis Pharmaceuticals | $34.34 | $51.68 | 50.50% | Buy |
| BPMC | Blueprint Medicines | $88.69 | $109.71 | 23.70% | Buy |
| AMLX | Amylyx Pharmaceuticals | $4.76 | $5.33 | 11.97% | Buy |
| INCY | Incyte | $75.87 | $84.56 | 11.45% | Buy |
| PRQR | ProQR Therapeutics | $3.82 | $3.63 | -4.97% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |